A New Immunochemical Strategy for Triple-Negative Breast Cancer Therapy

Following conjugation to β-lactam-derivatized monomethyl auristatin F, tropomyosin receptor kinase B cell surface protein-targeting dual variable domain-antibody–drug conjugates showed potency against multiple breast cancer cell lines, including TNBC cell lines.